APOE Genotype, Lipids, and Coronary Heart Disease Risk: A Prospective Population Study
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The risk of coronary heart disease (CHD) may be related to genetic mutations in the production of apolipoprotein E via alterations to the metabolism of CHD-related blood lipids such as low-density lipoprotein cholesterol and triglycerides. METHODS: The relationship between APOE genotype (*E3/*E3, *E3/*E4, *E2/*E3, *E4/*E4, *E2/*E4, and *E2/*E2) and fatal and nonfatal CHD was examined among 10 035 men and 12 134 women, aged 440 to 79 years, from the Norfolk, England, arm of the European Prospective Into Nutrition and Cancer Study (1993-2007). During an average of 11 years of follow-up, 2712 CHD events were documented. RESULTS: The hazard ratio for CHD was 0.88 (95% confidence interval, 0.77-0.99) for *E2 carriers (*E2/*E2 and *E2/*E3) and 1.09 (1.00-1.19) for *E4 carriers (*E3/*E4 and *E4/*E4) compared with homozygous *E3/*E3 individuals after age and sex adjustment. Similar values were obtained when systolic blood pressure, body mass index, diabetes mellitus, alcohol intake, physical activity, and smoking were added to the model. After additional adjustment for baseline levels of the ratio of low- to high-density lipoprotein cholesterol, the hazard ratios (and 95% confidence intervals) for *E2 and *E4 carriers were 0.97 (0.85-1.10) and 1.06 (0.97-1.15), respectively, when compared with *E3 homozygotes. No interactions by sex, smoking status, or age groups were observed. CONCLUSION: In the largest prospective cohort study to date, CHD risk was not associated with APOE genotype after controlling for a variety of cardiovascular risk factors, particularly the ratio of low- to high-density lipoprotein cholesterol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Association of apolipoprotein E genotypes with lipid levels and coronary risk
Bennet, A. M., Di Angelantonio, E., Ye, Z., Wensley, F., Dahlin, A., Ahlbom, A., Keavney, B., Collins, R., Wiman, B., de Faire, U., et al. (2007) · JAMA · doi:10.1001/jama.298.11.1300 · Cited by 794
Day, N., Oakes, S., Luben, R., Khaw, K., Bingham, S., Welch, A., & Wareham, N. (1999) · Nature · doi:10.17863/cam.89388 · Cited by 780
Self-citationWeisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34954-8 · Cited by 673
Apolipoprotein E Alleles and Risk of Coronary Disease: A Meta-analysis
Wilson, P. W. F., Schaefer, E. J., Larson, M. G., & Ordovas, J. M. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.10.1250 · Cited by 539
Meta-Analysis: Apolipoprotein E Genotypes and Risk for Coronary Heart Disease
Song, Y., Stampfer, M. J., & Liu, S. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-2-200407200-00013 · Cited by 528 · cited 2×
“Relative to the *E3/*E3 group, carriers of the *E2 allele tend to have increased levels of ApoE and decreased LDL-C, whereas *E4 carriers tend to have decreased ApoE and increased high-density lipoprotein cholesterol (HDL-C) levels.(1,2,5) It has been estimated that between 1% and 8% of variation in LDL-C level can be…”
BackgroundResultApolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study
Wilson, P. W. F. (1994) · JAMA · doi:10.1001/jama.1994.03520210050031 · Cited by 468 · cited 2×
“were not at increased risk of CHD.(17,20,31) The lack of agreement across the aforementioned studies may be owing to the heterogeneity of smoking prevalence, choice of reference group, study design, and classification of smoking history.”
BackgroundAssociation of APOE genotype with carotid atherosclerosis in men and women
Elosua, R., Ordovas, J. M., Cupples, L. A., Fox, C. S., Polak, J. F., Wolf, P. A., D’Agostino, R. A., & O’Donnell, C. J. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400114-jlr200 · Cited by 101
Frikke-Schmidt, R., Tybjærg-Hansen, A., Steffensen, R., Jensen, G., & Nordestgaard, B. G. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00520-9 · Cited by 77
Cited by
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570
Candidate Gene–Environment Interaction Research: Reflections and Recommendations
Dick, D. M., Agrawal, A., Keller, M. C., Adkins, A., Aliev, F., Monroe, S., Hewitt, J. K., Kendler, K. S., & Sher, K. J. (2015) · Perspectives on Psychological Science · doi:10.1177/1745691614556682 · Cited by 361
APOE2 enhances neuroprotection against Alzheimer’s disease through multiple molecular mechanisms
Conejero-Goldberg, C., Gomar, J. J., Bobes-Bascaran, T., Hyde, T. M., Kleinman, J. E., Herman, M. M., Chen, S., Davies, P., & Goldberg, T. E. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.194 · Cited by 199
“14 ApoE is expressed primarily in astrocytes and delivers cholesterol and other lipids to neurons through the low-density lipoprotein receptor family (including LDLR, LRP1, VLDLR and ApoER2).”
McKay, G. J., Silvestri, G., Chakravarthy, U., Dasari, S., Fritsche, L. G., Weber, B. H., Keilhauer, C. N., Klein, M. L., Francis, P. J., Klaver, C. C., et al. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwr015 · Cited by 105
“These include coronary heart disease events (2), atherosclerosis (3), age-related macular degeneration (AMD) (4), Alzheimer’s disease (5), and other dementias (6).”
BackgroundHinney, A., Albayrak, Ö., Antel, J., Volckmar, A., Sims, R., Chapman, J., Harold, D., Gerrish, A., Heid, I. M., Winkler, T. W., et al. (2014) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32234 · Cited by 46
“The isoforms are relevant for the interactions of APOEwith lipoprotein receptors [Weisgraber, 1994; Frikke-Schmidt et al., 2000; Bennet et al., 2007; Ward et al., 2009; Petkeviciene et al., 2012].”
BackgroundGustavsson, J., Mehlig, K., Leander, K., Strandhagen, E., Björck, L., Thelle, D. S., Lissner, L., Blennow, K., Zetterberg, H., & Nyberg, F. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.10.011 · Cited by 41
Metadata
- Authors
- Ward, H., Mitrou, P. N., Bowman, R., Luben, R., Wareham, N. J., Khaw, K.-T., & Bingham, S.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2009-08-10
- Volume
- 169
- Issue
- 15
- Pages
- 1424
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2133959779
- Cited by
- 85
- References
- 10
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.